Kymera Therapeutics, Inc. (NASDAQ:KYMR) has seen a significant insider transaction involving director Bruce Booth, who reported the sale of 500,000 shares of the company’s common stock. The total value of these sales reached $56,460,136. The transactions were executed on two separate dates, June 26 and June 29, 2026. During this period, the price per share ranged from $105.78 to $118.66. The reported prices for these transactions are weighted averages, reflecting the execution of shares in multiple transactions within the specified price ranges.
These sales were conducted pursuant to a Rule 10b5-1 trading plan, which was initially adopted on December 11, 2025. The shares sold were held indirectly by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. Mr. Booth serves as a member of the general partners for these funds. However, he disclaims beneficial ownership of the securities held by these entities, except to the extent of his pecuniary interest. Following these sales, Mr. Booth’s indirect holdings in Kymera Therapeutics common stock through the Atlas Venture funds have been adjusted accordingly.
The timing of these sales occurs against a backdrop of substantial stock price movement for Kymera Therapeutics. KYMR shares are currently trading at $114.69, representing a 150% increase over the past year. Despite this strong performance, InvestingPro analysis suggests that the stock is currently overvalued relative to its Fair Value. An InvestingPro tip notes that the stock is in overbought territory, with comprehensive analysis available in the Pro Research Report covering KYMR and 1,400+ other US equities. This valuation perspective highlights the contrast between the stock's recent price appreciation and fundamental assessments.
In parallel with the insider activity, Kymera Therapeutics has announced significant clinical progress. The company has completed enrollment in its Phase 2b BROADEN2 trial for KT-621, an oral STAT6 degrader designed for moderate to severe atopic dermatitis. This enrollment was completed nearly six months ahead of schedule. The accelerated enrollment allows the company to move up its expected topline data release to year-end 2026, which is earlier than the previously projected mid-2027 timeline.
This accelerated clinical timeline has prompted several analyst firms to adjust their outlooks on Kymera Therapeutics. Truist Securities raised its price target for Kymera Therapeutics shares to $136 from $116, maintaining a Buy rating. The firm cited the accelerated timelines and recent biotech merger activities as key factors. Canaccord Genuity also increased its price target to $129 from $106, maintaining a Buy rating due to the trial’s swift progress. Similarly, B.Riley raised its price target to $155 from $117, highlighting the expedited enrollment and its impact on the expected data release timeline. These developments reflect Kymera’s ongoing advancements in its clinical trials and the positive reception from the investment community.
The stock price data indicates that KYMR closed at $114.69, up $5.37 or 4.91%. After hours trading showed minimal movement at $114.67. The stock's performance over various timeframes, including 1D, 1W, 1M, 6M, 1Y, 5Y, and Max, reflects its volatility and recent surge. The combination of insider sales, valuation concerns, and clinical advancements creates a complex picture for investors monitoring Kymera Therapeutics.